MAY 09, 2017 09:00 PM PDT
Use of protein expression system for Influenza mucosal vaccine research
Presented at the 2017 Gibco ExpressionWorld Virtual Event
7 3 353

  • Director of the Department of Pathology, National Institute of Infectious Diseases
      Hideki Hasegawa graduated from the Hokkaido University school of medicine in 1993 with M.D. and finished graduate school at Hokkaido University in 1997 with Ph.D. He studied at the Rockefeller University from 1995 to 1996, and University College Dublin from 1996 to 1997 as a postdoctoral fellow. After finishing his studies he joined to National Institute of Infectious Diseases (NIID) where he had spent his research of infectious diseases at the department of pathology. In 2003 he promoted to Chief of Laboratory of Infectious Diseases Pathology, at NIID where he is extending his research to the development of a mucosal vaccine against influenza viruses. In 2011 he promoted to Director of the Department of Pathology at NIID.


    In the study of a mucosal vaccine for influenza, we need to evaluate the immune responses against vaccine in the serum and nasal washes. Serum IgG antibodies and mucosal secretory IgA antibodies are needed to evaluate. We use the mammalian protein expression system to produce the strain-specific influenza virus HA proteins to check the antibody titers. Moreover, we take the advantage of the expression system to produce the antibodies itself which were induced by the mucosal vaccine to characterize the effectiveness of the vaccine.

    Show Resources
    Loading Comments...
    Show Resources